Literature DB >> 2947417

Serum amyloid A protein, albumin and prealbumin in Alzheimer's disease and in demented patients with Down's syndrome.

I Elovaara, C P Maury, J Palo.   

Abstract

The concentrations of serum amyloid A (SAA) protein, albumin and prealbumin were measured in 22 patients with Alzheimer's disease (AD), in 21 demented patients with Down's syndrome (DS), and in age-matched control subjects for both groups in a 2-year follow-up study. The concentration of SAA was initially elevated in 9 of 22 (41%) patients with AD and in 8 of 21 (38%) patients with DS. After 2-years, 10 of 12 (83%) AD patients and 11 of 14 (79%) DS patients had elevated SAA levels but with fluctuation of the values. None of the controls revealed increase in the SAA level. The concentration of SAA did not correlate with the duration of AD or AD-like process although the highest values were found in cachectic AD patients confined to bed. Although neoplasm or infection were not diagnosed, the presence of occult neoplasm or subclinical infection as a cause of SAA elevation, especially in the DS group susceptible to infection, could not be excluded. Moreover, the fluctuation of SAA values in DS seems likely to be associated with an infection. Albumin and prealbumin levels were decreased in both AD and DS; the prealbumin levels in AD was lower than that in DS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2947417     DOI: 10.1111/j.1600-0404.1986.tb07863.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  8 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

Authors:  A L Schwarzman; L Gregori; M P Vitek; S Lyubski; W J Strittmatter; J J Enghilde; R Bhasin; J Silverman; K H Weisgraber; P K Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

3.  Immunodetection of the amyloid P component in Alzheimer's disease.

Authors:  T Duong; E C Pommier; A B Scheibel
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Serum Amyloid A is Expressed in the Brain After Traumatic Brain Injury in a Sex-Dependent Manner.

Authors:  Sirena Soriano; Bridget Moffet; Evan Wicker; Sonia Villapol
Journal:  Cell Mol Neurobiol       Date:  2020-02-14       Impact factor: 5.046

5.  Serum albumin, cognitive function, motor impairment, and survival prognosis in Parkinson disease.

Authors:  Shujun Sun; Yiyong Wen; Yandeng Li
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

6.  Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: implications for Alzheimer disease.

Authors:  Helen F Stanyon; John H Viles
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

7.  Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.

Authors:  Walter Maetzler; Youyong Tian; Stephanie Maria Baur; Tina Gauger; Bartholomäus Odoj; Benjamin Schmid; Claudia Schulte; Christian Deuschle; Susanna Heck; Anja Apel; Arthur Melms; Thomas Gasser; Daniela Berg
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

Review 8.  Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer's Disease?

Authors:  Federica Saponaro; Jin Hae Kim; Grazia Chiellini
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.